ePrints

Breast cancer resistance protein BCRP (ABCG2)-mediated transepithelial nitrofurantoin secretion and its regulation in human intestinal epithelial (Caco-2) layers

Lookup NU author(s): Jamie Wright, Professor Nicholas Simmons

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

In order to determine the capacity and regulation of the breast cancer resistance protein (BCRP)-mediated transport in intact human intestinal epithelial monolayers (Caco-2) in which multiple ABC transporters are expressed, nitrofurantoin has been used as a selective transported substrate. Nitrofurantoin transepithelial secretion was confirmed in both human BCRP and mouse bcrp-transfected MDCKII epithelia, whereas no net transepithelial secretion was observed in native or human MDR1-MDCKII epithelia. Furthermore, nitrofurantoin transepithelial secretion by BCRP-MDCKII monolayers was inhibited by Ko143 (10 mu M), but not verapamil (100 mu M). In Caco-2 cells grown upon permeable supports, nitrofurantoin displayed a dose-dependent transepithelial secretion with an apparent Km = 69.41 +/- 22.3 mu M and Vmax = 14.03 +/- 2.27 nmol/(cm(2).h). Net nitrofurantoin transepithelial secretion by Caco-2 epithelia was inhibited 92% by 10 mu M Ko143. Regulation of expression and function of BCRP in Caco-2 epithelial monolayers was determined after 72-h pre-exposure of the monolayers to a number of potential inducing agents. Quantitative real-time PCR and Western blotting were used to correlate induction of BCRP transcript and protein levels with transport activity. 72-h pre-treatment with beta-napthoflavone and rosiglitazone up-regulates BCRP mRNA and protein expression and transport of nitrofurantoin. Ko143-sensitive transepithelial secretion of the bi-substrate (MDR1/BCRP) prazosin was also increased in the presence of rosiglitazone. We conclude that nitrofurantoin may be used to unambiguously measure BCRP-mediated fluxes in Caco-2 epithelial layers. Since dynamic regulation of BCRP expression and function is retained, the Caco-2 cell-line is useful as a screen for drug-drug and drug-diet interactions mediated by BCRP. (C) 2011 Elsevier B.V. All rights reserved.

Publication metadata

Author(s): Wright JA, Haslam LS, Coleman T, Simmons NL

Publication type: Article

Publication status: Published

Journal: European Journal of Pharmacology

Year: 2011

Volume: 672

Issue: 1-3

Pages: 70-76

Print publication date: 10/10/2011

ISSN (print): 0014-2999

ISSN (electronic): 1879-0712

Publisher: Elsevier BV

URL: http://dx.doi.org/10.1016/j.ejphar.2011.10.004

DOI: 10.1016/j.ejphar.2011.10.004

Altmetrics

Share